Skip to main content

Table 1 Patient disposition

From: EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex

n (%) Everolimus
FAS (N = 120)
Everolimus pediatric subpopulation
(N = 90)
Patients
 Completed study 100 (83.3) 79 (87.8)
 Discontinued 20 (16.7) 11 (12.2)
Primary reason for premature discontinuation
 Adverse event(s) 8 (6.7) a 4 (4.4)
 Otherb 5 (4.2) 3 (3.3)
 Subject withdrew consent 5 (4.2) 2 (2.2)
 Administrative problems 1 (0.8) 1 (1.1)
 SEGA progression 1 (0.8) 1 (1.1)
  1. FAS full analysis set, SEGA subependymal giant cell astrocytoma
  2. aIncludes abnormal laboratory values
  3. bIncludes investigator’s decision and mother’s decision